Paclitaxel: a review of adverse toxicities and novel delivery strategies.
Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.
Marupudi
Neena I
NI
Johns Hopkins School of Medicine, Department of Neurological Surgery, Meyer 7-113, 600 North Wolfe Street, Baltimore, MD 21287, USA.
Han
James E
JE
Li
Khan W
KW
Renard
Violette M
VM
Tyler
Betty M
BM
Brem
Henry
H
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects* / Q000737:chemistry
D017239:Paclitaxel